News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘LungCancer’ clear

  • Dana-Farber Cancer Institute and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.

Tags: LungCancer, Partnerships

  • The National Cancer Institute (NCI) has launched a new nationwide clinical trial to find out if two molecularly targeted drugs that have improved outcomes in advanced lung cancer can increase survival of patients with early-stage lung cancer that has been surgically removed.

Tags: LungCancer, TargetedTherapy

  • Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.

Tags: BasicResearch, LungCancer

  • Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science are collaborating with Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc., to identify which lung cancer patients would benefit from a new generation of immunotherapies and which combination of such therapies will be the most effective.

Tags: BasicResearch, LungCancer, Immunotherapy

  • A new study shows about half of non-small cell lung cancer (NSCLC) patients whose tumors no longer responded to conventional targeted drugs had their tumors shrink after receiving a new, more precisely targeted agent.

Tags: EGFR, LungCancer

  • A study 10 years ago discovered a gene mutation that could be treated by a drug that was on the market for something else and changed the way lung cancer patients are treated. It was the start of the era of precision medicine in lung cancer and transformed treatment of the disease.

Tags: EGFR, LungCancer, TargetedTherapy

  • Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells.

Tags: LungCancer, Immunotherapy

  • Dana-Farber researchers have found that a combination of two already-in-use drugs may have an effect on stopping the growth of the most common genetic subtype of lung cancer setting the stage for clinical trials.

Tags: LungCancer, TargetedTherapy

  • Cancer death rates in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer, published online by the journal Cancer.

Tags: BreastCancer, ColonCancer, LungCancer, Prevention

  • Scientists at Dana-Farber Cancer Institute and the University of Colorado Cancer Center report on a gene fusion that spurs the cells to divide rapidly. Treating the cells with a compound that blocks the protein caused the cells to die which may offer a targeted therapy in patients.

Tags: BasicResearch, LungCancer

Showing 1-10 of 31 items